We are delivering transformational medicines through the understanding of protein-ligand interactions.
New Generation of Menin Inhibitors
Most Acute Myeloid Leukemia (AML) therapies try to kill leukemic cells. But what if you could reprogram them instead, preventing the interaction that keeps it cancerous? That’s the promise of menin inhibitors. And CHARM is taking this one step further with a new generation of menin inhibitors designed to overcome treatment resistance.
Our Approach
Founded by leaders with a track record in AI and drug discovery, the CHARM team is now focused on demonstrating the potential for its next generation menin inhibitors in the clinic.
Designing structurally optimised inhibitors that are highly potent and bind precisely within the KMT2A interface on menin.
About
